Comparing prophylaxis with episodic treatment in haemophilia A: implications for clinical practice.
Recurrent haemarthroses in patients with severe haemophilia A often result in irreversible joint damage. Treatment using routine infusions of factor VIII (FVIII) concentrate, a therapy known as prophylaxis, is currently recommended for the prevention of haemarthroses and arthropathy in persons with severe haemophilia A. However, until recently, the body of evidence supporting prophylaxis in comparison with FVIII infusions given only at the time of haemarthroses was mostly retrospective and anecdotal. Recently, two prospective randomized clinical trials have been conducted to compare prophylaxis with on-demand FVIII treatment for the prevention of arthropathy and haemarthroses in young children with haemophilia A. A third prospective, non-randomized trial evaluated a strategy of escalating the dose frequency of prophylaxis. Data from these studies will provide objective evidence for the prevention of haemarthroses and arthropathy in children with severe haemophilia A.
Manco-Johnson
M
M
Mountain States Regional Hemophilia & Thrombosis Center, Department of Pediatrics, University of Colorado, Denver and Health Sciences Center, Denver, Colorado, USA. Marilyn.Manco-Johnson@UCHSC.edu
D000293:Adolescent; D000328:Adult; D002648:Child; D002675:Child, Preschool; D003029:Coagulants / Q000008:administration & dosage*; D005169:Factor VIII / Q000008:administration & dosage* / Q000187:drug effects; D006395:Hemarthrosis / Q000188:drug therapy / Q000503:physiopathology / Q000517:prevention & control*; D006467:Hemophilia A / Q000188:drug therapy*; D006801:Humans; D007223:Infant
D003029:Coagulants; D005169:Factor VIII